论文部分内容阅读
目的 探讨影响153 Sm 乙二胺四亚甲基磷酸盐 (EDTMP)治疗转移癌性骨痛疗效的相关因素。方法 按国际原子能机构区域合作计划组织中国多中心研究 ,3年内收集153 Sm EDTMP治疗转移癌性骨痛 2 34例 ,根据治疗响应分为有效及无效 2组 ,比较其个人情况 ,临床特点 ,原发病种 ,骨转移特点及治疗方法等因素 ,以SAS软件进行分组与多因素分析。结果 183例治疗有效 ,5 1例治疗无效 ,2组间在年龄、非核素治疗、153 Sm EDTMP用量、转移灶数目、占骨骼比重、放射性摄取程度等方面无明显差别。但无效组中男性 (4 3例 ,84.3% )、肺癌 (34例 ,6 6 .7% )、脊柱、骨盆与下肢转移的比例明显不同于有效组。多因素分析证实患者性别、肿瘤类型和转移部位与治疗效果相关。结论 153 Sm EDTMP治疗对肺癌、男性和下半身转移者效果可能较差
Objective To investigate the factors that affect the efficacy of 153 Sm ethylenediamine tetramethylene phosphate (EDTMP) in the treatment of metastatic cancerous bone pain. Methods According to the multi-center study conducted by IAEA Regional Cooperation Program, 234 patients with metastatic cancerous bone pain were collected during 153 years. According to the response, the patients were divided into two groups: effective and ineffective. Personal characteristics, clinical features, Incidence of disease, bone metastasis characteristics and treatment methods and other factors, SAS software grouping and multivariate analysis. Results 183 cases were effective and 51 cases were ineffective. There was no significant difference between the two groups in terms of age, non-radionuclide therapy, dosage of 153 Sm EDTMP, number of metastases, proportion of bone, radioactivity uptake. However, the proportion of men (43 cases, 84.3%), lung cancer (34 cases, 66.7%), spine, pelvis and lower extremity metastasis in the invalid group was significantly different from that in the effective group. Multivariate analysis confirmed that the patient’s gender, tumor type, and metastasis were related to treatment outcome. Conclusion 153 Sm EDTMP treatment may be less effective in lung cancer, men and lower body metastases